[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Deafness & Hearing Loss |
|
|
Clinical Trial: Efficacy and Safety of Donepezil in Subjects with Mild Cognitive Impairment
This study is currently recruiting patients.
|
Purpose
The purpose of this study will be to investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior. Brain imaging will also be performed in some subjects.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Memory Loss | Drug: Donepezil Hydrochloride | Phase IV |
MedlinePlus related topics: Memory
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Protocol E2020-A001-412: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects with Mild Cognitive Impairment (MCI)
Secondary Outcomes: Behavioral, global and cognitive outcomes; Neuroimaging
Expected Total Enrollment: 550
Study start: December 2003; Expected completion: March 2007
Last follow-up: May 2006; Data entry closure: November 2006
Eligibility
Ages Eligible for Study: 45 Years - 90 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Memory complaint
- Mini Mental Status Exam (MMSE) score 24-28 inclusive
- General cognition and function performance sufficiently preserved such that a diagnosis of Alzheimer’s disease (AD) cannot be made
- Generally healthy and ambulatory
- Sufficiently fluent in English
Exclusion Criteria:
- Diagnosis of probable or possible AD
- Neurological disorders
- History of malignant cancers
- Previously have taken donepezil or other acetylcholinesterase (ChE) inhibitors for more than 1 month or in the past 3 months prior to study entry
Location and Contact Information
Nicola Lynch nicola_lynch@eisai.com
Alabama
Albaster, Alabama, United States; Recruiting
Arizona
Peoria, Arizona, United States; Recruiting
Mesa, Arizona, United States; Recruiting
Sun City, Arizona, United States; Recruiting
Tucson, Arizona, United States; Recruiting
California
Sacramento, California, United States; Recruiting
Irvine, California, United States; Recruiting
San Francisco, California, United States; Recruiting
Fresno, California, United States; Recruiting
Irvine, California, United States; Recruiting
San Diego, California, United States; Recruiting
San Diego, California, United States; Recruiting
Garden Grove, California, United States; Recruiting
Colorado
Denver, Colorado, United States; Recruiting
Connecticut
New Haven, Connecticut, United States; Recruiting
Florida
Venice, Florida, United States; Recruiting
West Palm Beach, Florida, United States; Recruiting
Jacksonville, Florida, United States; Recruiting
Fort Lauderdale, Florida, United States; Recruiting
Ocala, Florida, United States; Recruiting
Sarasota, Florida, United States; Recruiting
St. Petersburg, Florida, United States; Recruiting
West Palm Beach, Florida, United States; Recruiting
Tampa, Florida, United States; Recruiting
Fort Meyers, Florida, United States; Recruiting
Hollywood, Florida, United States; Recruiting
North Miami, Florida, United States; Recruiting
Sarasota, Florida, United States; Recruiting
Boynton Beach, Florida, United States; Recruiting
Melbourne, Florida, United States; Recruiting
Georgia
Snellville, Georgia, United States; Recruiting
Illinois
Chicago, Illinois, United States; Recruiting
Indiana
Elkhart, Indiana, United States; Recruiting
Kentucky
Paducah, Kentucky, United States; Recruiting
Louisiana
New Orleans, Louisiana, United States; Recruiting
Michigan
Farmington Hills, Michigan, United States; Recruiting
Kalamazoo, Michigan, United States; Recruiting
Nevada
Las Vegas, Nevada, United States; Recruiting
New Jersey
Kenilworth, New Jersey, United States; Recruiting
Long Branch, New Jersey, United States; Recruiting
New York
New York, New York, United States; Recruiting
Lexington, New York, United States; Recruiting
Albany, New York, United States; Recruiting
Rochester, New York, United States; Recruiting
Staten Island, New York, United States; Recruiting
North Carolina
No. Charleston, North Carolina, United States; Recruiting
Ohio
Cleveland, Ohio, United States; Recruiting
Toledo, Ohio, United States; Recruiting
Centerville, Ohio, United States; Recruiting
Oregon
Medford, Oregon, United States; Recruiting
Portland, Oregon, United States; Recruiting
Pennsylvania
Pittsburgh, Pennsylvania, United States; Recruiting
Greensberg, Pennsylvania, United States; Recruiting
Rhode Island
Providence, Rhode Island, United States; Recruiting
Tennessee
Madison, Tennessee, United States; Recruiting
Texas
Houston, Texas, United States; Recruiting
Houston, Texas, United States; Recruiting
San Antonio, Texas, United States; Recruiting
Wichita Falls, Texas, United States; Recruiting
Austin, Texas, United States; Recruiting
Utah
Salt Lake City, Utah, United States; Recruiting
Vermont
Bennington, Vermont, United States; Recruiting
Virginia
Charlottesville, Virginia, United States; Recruiting
Washington
Seattle, Washington, United States; Recruiting
More Information
Record last reviewed: December 2004
Last Updated: January 21, 2005
Record first received: December 22, 2004
ClinicalTrials.gov Identifier: NCT00100022
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- (National Women's Health Information Center, OWH, HHS)
- 1999 Federal Government TTY Directory (Federal Citizen Information Center, GSA)

Not Signed In -


